-
公开(公告)号：US20250041221A1
公开(公告)日：2025-02-06
申请号：US18715327
申请日：2022-12-02
Applicant: Universite Claude Bernard Lyon 1 , Centre National de la Recherche Scientifique , Hospices Civils De Lyon , INSERM (Institut National de la Santé et de la Recherche Médicale) , Universita Degli Studi Di Verona
Inventor： Giovanna Lollo , Valentina Andretto , David Kryza , Eyad Al Mouazen , Mathieu Repellin , Stéphanie Briancon , Laurent Schaeffer , Jacquier Arnaud , Laurent Coudert
IPC: A61K9/127 , A61K9/51 , A61K31/7105 , A61K31/711
Abstract: The invention relates to a nanoparticle comprising at least one cationic lipid, at least one neutral lipid, and at least one pH sensitive lipid which differs from said cationic lipid, which can be used as a vector for the transport and release of nucleic acids within cells.
-
公开(公告)号：US20240424134A1
公开(公告)日：2024-12-26
申请号：US18517548
申请日：2023-11-22
Inventor： Yong-beom LIM , You-Jin JUNG , Hyoseok KIM
IPC: A61K48/00 , A61K31/7105 , A61K31/711 , A61K41/00 , C07K1/107 , C07K7/06 , C07K7/08 , C12N15/113
Abstract: The present disclosure relates to a novel hydrophobic peptide consisting of short amino acid sequences as repeat units, having a perfectly stabilized α-helix structure without help from outside. The peptide has no cytotoxicity and has magnetic responsiveness, i.e., its arrangement and orientation are controlled by a magnetic field. In addition, the hydrophobic peptide according to the present disclosure can not only form complexes of various structures with hydrophilic molecules but also provide suitable nanostructures such as nanoribbons and artificial chromosome-like structures through stepwise association with nucleic acid materials.
-
3.发明申请
公开(公告)号：US20240423972A1
公开(公告)日：2024-12-26
申请号：US18263381
申请日：2022-02-01
Applicant: Yale University
Inventor： Hee-Won Suh , Julia M. Lewis , W. Mark Saltzman , Michael Girardi
IPC: A61K31/4745 , A61K9/51 , A61K31/711 , A61K47/54 , A61K47/69 , A61P35/00
Abstract: A bioadhesive nanoparticle (BNP) for long-lasting local drug delivery to treat cancer was developed. The bioadhesive nanoparticles (BNP) are composed of biodegradable polymer such as poly(lactic acid)-hyperbranched polyglycerol (PLA-HPG), encapsulating a chemotherapeutic such as camptothecin (CPT). Nanoparticles (NPs) of PLA-HPG are non-adhesive NPs (NNPs), which are stealthy in their native state, but conversion of the vicinal diols of HPG to aldehydes confers the ability to form strong covalent bonds with amine-rich surfaces. The formulation is administered in combination with immunostimulatory molecules such as CPG and shows unexpectedly better killing of cancer cells.
-
公开(公告)号：US12171740B2
公开(公告)日：2024-12-24
申请号：US18080057
申请日：2022-12-13
Applicant: CHILDREN'S HOSPITAL MEDICAL CENTER
Inventor： Nurit P. Azouz , Marc E. Rothenberg
IPC: A61K31/352 , A61K31/37 , A61K31/7088 , A61K31/7105 , A61K31/711 , A61K38/00 , A61K38/55 , A61K38/57 , A61K39/395 , A61P37/08 , C12N15/113
Abstract: Provided are methods for increasing SPINK7 anti-proteinase activity in a target tissue of a subject having an allergic inflammatory condition characterized by inflammation of a squamous epithelium in the target tissue, the method comprising inhibiting kallikrein 5 (KLK5) proteinase activity in the target tissue. Suitable KLK5 inhibitors may include a KLK5-Fc fusion protein, a KLK5 anti-sense polynucleotide, a KLK5-directed miRNA, a KLK5-directed shRNA, a KLK5-directed antibody, or a coumarin compound such as 3-(3-chlorophenyl) carboxy-7-hydroxymethyl coumarin or 3-carboxy-7-hydroxymethyl coumarin.
-
公开(公告)号：US20240417738A1
公开(公告)日：2024-12-19
申请号：US18703637
申请日：2022-10-24
Applicant: Ohio State Innovation Foundation
Inventor： Chun-Tien KUO , Zhongkun ZHANG , Robert LEE
IPC: C12N15/113 , A61K9/00 , A61K9/127 , A61K9/51 , A61K31/01 , A61K31/4745 , A61K31/7084 , A61K31/711 , A61P35/00
Abstract: Disclosed are compositions and methods for the treatment of cancer. For example, provided herein are pharmaceutical composition comprising a lipid particle encapsulating a first TLR agonist and a second TLR agonist, as well as methods of using thereof to treat or prevent cancer. Also provided herein are pharmaceutical compositions comprising a lipid particle encapsulating a TLR agonist and an antisense oligonucleotide capable of reducing expression of PD-L1 in a target cell, as well as methods of using thereof to treat or prevent cancer.
-
公开(公告)号：US12138346B2
公开(公告)日：2024-11-12
申请号：US18368097
申请日：2023-09-14
Applicant: LEMONEX INC.
Inventor： Cheolhee Won
IPC: A61K9/16 , A61K31/203 , A61K31/44 , A61K31/4745 , A61K31/704 , A61K31/711 , A61K31/713 , A61K38/17 , A61K38/46 , A61K39/395
Abstract: A bioactive substance delivery system includes a bioactive substance comprising nucleic acid, and a bioactive substance carrier comprising a porous silica particle having a plurality of pores with a diameter of 5 nm to 100 nm, and having not less than 24 hours at which a ratio of absorbance is ½. The porous silica particles may be positively charged inside the pore at neutral pH.
-
公开(公告)号：US20240299312A1
公开(公告)日：2024-09-12
申请号：US18023564
申请日：2023-02-24
Applicant: Cureport Inc.
Inventor： De-Min Zhu
IPC: A61K9/51 , A61K31/7105 , A61K31/711 , C12N15/88
CPC classification number: A61K9/5146 , A61K9/5123 , A61K9/5192 , A61K31/7105 , A61K31/711 , C12N15/88
Abstract: Disclosed herein are nanoparticle compositions including a polymer component and a lipid component. The disclosure also relates to lipid nanoparticles (LNPs) having the nanoparticle composition for nucleic acid delivery, and methods of making and using the same. The LNPs can be used for fast, efficient and safe delivery of nucleic acid (e.g., DNA/RNA).
-
公开(公告)号：US20240285796A1
公开(公告)日：2024-08-29
申请号：US18612564
申请日：2024-03-21
Applicant: Generation Bio Co.
Inventor： Matthew G. Stanton , Birte Nolting , Andrew Milstead
IPC: A61K48/00 , A61K9/51 , A61K31/7105 , A61K31/711 , A61K47/24 , A61K47/28 , C07C229/12
CPC classification number: A61K48/0033 , A61K9/5123 , A61K31/7105 , A61K31/711 , A61K47/24 , A61K47/28 , C07C229/12
Abstract: Provided herein are lipids having the Formula I or Formula Ia:
and pharmaceutically acceptable salts thereof, wherein R′, R1, R2, R3, R4, R5, R6a, R6b, X1, X2, and n are as defined herein for Formula I and Formula Ia, respectively. Also provided herein are lipid nanoparticle (LNP) compositions comprising lipid having the Formula I or Ia and a capsid-free, non-viral vector (e.g., ceDNA). In one aspect of any of the aspects or embodiments herein, these LNPs can be used to deliver a capsid-free, non-viral DNA vector to a target site of interest (e.g., cell, tissue, organ, and the like).
-
公开(公告)号：US12059477B2
公开(公告)日：2024-08-13
申请号：US17579115
申请日：2022-01-19
Applicant: Beam Therapeutics Inc.
Inventor： Cory Dane Sago , Gregory Lawrence Hamilton
IPC: A61K47/69 , A61K31/7105 , A61K31/711 , A61K47/24 , A61K47/26 , A61P1/16 , C07C219/06 , C07D295/13
CPC classification number: A61K47/6929 , A61K31/7105 , A61K31/711 , A61K47/24 , A61K47/26 , A61P1/16 , C07C219/06 , C07D295/13
Abstract: The present disclosure describes compositions, preparations, nanoparticles (such as lipid nanoparticles), and/or nanomaterials and methods of their use.
-
公开(公告)号：US20240252454A1
公开(公告)日：2024-08-01
申请号：US18289283
申请日：2022-05-02
Applicant: LEAD DISCOVERY CENTER GMBH , MAX-PLANCK-GESELLSCHAFT ZUR FÖRDERUNG DER WISSENSCHAFTEN E.V.
Inventor： Tim BERGBREDE , Raffaella DI LUCREZIA , Anke UNGER , Axel CHOIDAS , Bert KLEBL , Peter NUSSBAUMER , Sascha MENNINGER , Peter HABENBERGER , Gunther ZISCHINSKY , Uwe KOCH , Peter SCHRÖDER , Pavla JESTRABOVÁ , Lenka PALOVÁ-JELÍNKOVÁ , Klára DÁNOVÁ , Maria FALKENBERG-GUSTAFSSON , Laleh ARABANIAN , Claes GUSTAFSSON , Nils-Göran LARSSON , Lars PALMQVIST
IPC: A61K31/166 , A61K31/4184 , A61K31/453 , A61K31/47 , A61K31/496 , A61K31/5377 , A61K31/711 , A61P35/00
CPC classification number: A61K31/166 , A61K31/4184 , A61K31/453 , A61K31/47 , A61K31/496 , A61K31/5377 , A61K31/711 , A61P35/00
Abstract: The present invention relates to a composition comprising at least one inhibitor of mitochondrial transcription (IMT) and at least one anti-cancer drug. Furthermore, the present invention is directed to compositions for use as a medicament and to compositions for use in the treatment and/or prevention of cancer.
